Data from three phase III trials—PAPILLON, MARIPOSA, and MARIPOSA-2—highlight amivantamab, an EGFR–MET bispecific antibody, as a potential contender as a standard treatment for EGFR-mutant non–small cell lung cancer. Amivantamab paired with chemotherapy is a superior first-line option for patients with exon 20–mutated disease. Beyond this subset, compared with standard osimertinib, the combination with or without lazertinib also boosted progression-free survival, albeit at the cost of added toxicity.

You do not currently have access to this content.